Drug
chimeric antigen receptor gene modified T cells
chimeric antigen receptor gene modified T cells is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph not_applicable
2
67%
Ph early_phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (33.3%)
N/A2 (66.7%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
NCT07048353
recruitingnot_applicable
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
NCT06850285
recruitingnot_applicable
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NCT06783816
Clinical Trials (3)
Showing 3 of 3 trials
NCT07048353Early Phase 1
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
NCT06850285Not Applicable
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
NCT06783816Not Applicable
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3